Efficacy of ibandronate in metastatic bone disease: review of clinical data.

Abstract

Metastatic bone disease affects many cancer patients and has a significant disease burden because of complications such as pathologic fractures and severe pain, which affect patient mobility and quality of life. Bisphosphonates are the current standard of care for treating metastatic bone disease. Available agents have shown varying degrees of efficacy in clinical trials, and treatment potential can be limited by efficacy, tolerance, or toxicity issues. Ibandronate (Bondronat); F. Hoffman-La Roche Ltd., Basel, Switzerland, http://www.roche.com) is a highly potent, single-nitrogen bisphosphonate that is available in i.v. and oral formulations. In phase III trials in breast cancer patients, both formulations reduced the incidence of skeletal complications associated with metastatic bone disease and had significant and sustained effects on bone pain and patient quality of life. Open-label studies of loading-dose ibandronate administered over consecutive days suggest it also may be useful for relieving severe or opioid-resistant metastatic bone pain. New trials have been designed or are in progress that may extend the clinical indications of ibandronate for patients with metastatic bone disease.

• Authors: Richard Bell
• Journal: The oncologist (Oncologist) Vol. 10 Suppl 1 Pg. 8-13 ( 2005) ISSN: 1083-7159 [Print] England
• PMID: 16264107 (Publication Type: Journal Article, Review)

Chemical References

• Bone Density Conservation Agents
• Diphosphonates
• Ibandronic Acid

Topics

• Bone Density Conservation Agents (administration & dosage, therapeutic use)
• Bone Neoplasms (drug therapy, secondary)
• Breast Neoplasms (drug therapy, pathology)
• Clinical Trials as Topic
• Colorectal Neoplasms (drug therapy, pathology)
• Diphosphonates (administration & dosage, therapeutic use)
• Dose-Response Relationship, Drug
• Humans
• Ibandronic Acid
• Multiple Myeloma (drug therapy, pathology)
• Treatment Outcome